Clinical trials: BCG Vaccine
Non-Invasive Bladder Urothelial Carcinoma
Intravesical BCG: is the Urinary Bladder Ready to Receive it
Prospective cohort and Prospective observational study which aims To define the healing time-frame of the resected area of the bladder after TURBT.
- Trial name
- NCT05335512
- Volunteers
- 100 people
- Sponsor
- Tata Memorial Centre
Atopy, Asthma
Vitamin A Supplementation at Birth and Atopy in Childhood
INTRODUCTION Eight trials studying the effect of providing neonatal vitamin A supplementation (NVAS) have been reported, and another four are underway to test whether NVAS should become WHO policy.
- Conditions
- Atopy, Asthma, Eczema, Food Allergy
- Trial name
- NCT01779180
- Where
- Guinea-Bissau
- Volunteers
- 2,000 people
- Sponsor
- Bandim Health Project
Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating…
- Conditions
- Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
- Trial name
- NCT03091660
- Testing
- BCG Solution, BCG Tokyo-172 Strain Solution, BCG Tokyo-172 Strain Vaccine
- Where
- 174 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- SWOG Cancer Research Network
Non Specific Effects of Vaccine, Bacillus-Calmette-Guerin
Low Birth Weight Follow-up
The Randomized Control Trail included 4,172 low-birth weight children between February 2008 and September 2013 in Bissau. The children who were included in the RCT and who are living in the Bandim Health Project study area will…
- Conditions
- Non Specific Effects of Vaccine, Bacillus-Calmette-Guerin, Low Birth Weight, Maternal Immunisation
- Trial name
- NCT03020147
- Where
- Guinea-Bissau
- Volunteers
- 1,258 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Immunization Coverage
Mobile Nudges to Increase Early Vaccination Coverage in Rural Areas
Despite major progress made in vaccination coverage overall, timeliness of vaccines remains a key concern in many settings. At the same time, access to mobile phones has increased rapidly, offering new opportunities to track and…
- Trial name
- GEVaP (NCT03797950)
- Testing
- Voice Reminder (Group A), Cash Incentive (Group B)
- Where
- Ghana
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Swiss Tropical & Public Health Institute
Death, Infant, Morbidity;Infant
Trial to Compare Two Strains of BCG
The trial will be a two-year outcome assessor-blinded RCT at the maternity ward of hospital Simão Mendes (HNSM) in urban Bissau, Guinea-Bissau to compare BCG-Japan versus BCG-Russia 1:1 in 15,000 infants with respect to…
- Trial name
- STRAIN III (NCT04383925)
- Testing
- BCG-Japan, BCG-Russia
- Where
- Guinea-Bissau
- Volunteers
- 16,390 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Tuberculosis
Influence of Filarial Infections on Tuberculosis Disease and Tuberculosis Vaccination in Cameroon
Filarial nematodes modulate the host immune response to promote regulatory and T helper type 2 immune responses, which were shown to influence concomitant infections.
- Trial name
- MAP-TB (NCT04547738)
- Testing
- TB treatment according to national guidelines
- Where
- Cameroon
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
Mortality, Morbidity
Vitamin A With BCG Vaccine
Two studies from Asia have suggested a beneficial effect of vitamin A supplementation given at birth. Hypotheses: Vitamin A supplementation administered at birth together with BCG vaccination is associated with a 30% reduction in…
- Trial name
- NCT00168597
- Testing
- Vitamin A
- Where
- Guinea-Bissau
- Volunteers
- 4,800 people
- Sponsor
- Bandim Health Project
Tuberculosis
Can Screening People Registering With Primary Care Improve the Detection of Tuberculosis?
This randomised controlled trial tests whether screening people registering with general practices cost-effectively increases the detection of tuberculosis. The study objectives are to: 1.
- Trial name
- NCT00214708
- Testing
- Screening for Tuberculosis
- Where
- United Kingdom
- Sponsor
- Barts & The London NHS Trust
Tuberculosis
Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents
Randomized, Placebo Controlled, Partially Blinded Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection with Mycobacterium tuberculosis of AERAS-404 and BCG Revaccination in Healthy Adolescents
- Trial name
- NCT02075203
- Testing
- AERAS-404, Bacillus Calmette-Guérin (BCG)
- Where
- 2 sites in South Africa
- Volunteers
- 989 people, healthy volunteers welcome
- Sponsor
- Aeras
Non Muscle Invasive Bladder Cancer
Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)
The purpose of this clinical trial is to obtain long-term follow-up information and status of bladder cancer for patients who received study treatment in the QUILT-2.005 study.
- Trial name
- NCT05981131
- Testing
- N803 plus Bacillus Calmette-Guerin (BCG)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- ImmunityBio, Inc.
Vitamin D3, Chronic-granulomatous Disease
Vitamin D3 For CGD Patients With BCGosis/Itis
When children with chronic granulomatous disease (CGD) got BCG infection the treatment would be a tough task. The goal of the proposed research is to observe weather vitamin D supplementation can help the CGD children get through…
- Conditions
- Vitamin D3, Chronic-granulomatous Disease, BCG
- Trial name
- NCT03984890
- Testing
- Vitamin D3, Traditional treatment of CGD and TB
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Children's Hospital of Fudan University
Neuroblastoma, Sarcoma
Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody A1G4 with BCG may kill more tumor cells.
- Trial name
- NCT00003023
- Testing
- BCG vaccine, monoclonal antibody A1G4 anti-idiotype vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Urinary Bladder Cancer, Urinary Bladder Neoplasm
Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
There is a relation between inflammatory cells and the prognosis of tumors (cancer colon, renal, liver, and urinary bladder). In this study, the investigators will link the Neutrophils to Lymphocytes ratio to the response to…
- Conditions
- Urinary Bladder Cancer, Urinary Bladder Neoplasm, BCG, Trans Urethral Resection of a Bladder Tumor
- Trial name
- NCT05946369
- Testing
- Neutrophil to lymphocyte ratio
- Where
- Egypt
- Volunteers
- 96 people
- Sponsor
- Ain Shams University
LTBI, BCG Vaccination Reaction
Cytometric Immunodiagnostics of Latent Tuberculosis Infection (LTBI)
TB-reactive immune cells will be tested in a multiparametric flow cytometry to distinguish an immune response for antigens of Mycobacterium spp. in TB disease/latent infection or a reaction after BCG vaccine.
- Conditions
- LTBI, BCG Vaccination Reaction, TB
- Trial name
- NCT04673227
- Testing
- Blood draw
- Where
- 2 sites in Czechia
- Volunteers
- 120 people
- Sponsor
- Thomayer University Hospital
Tuberculosis
PPD Size and Mycobacteria Tuberculosis ELISPOT in Children Who Have Received BCG in Neonate Period
To investigate the size of PPD and TB specific ELISPOT among children between 3m/o and 15 y/o . Calculate the normal range of age specific PPD size in children who recieved BCG at new-born period.
- Trial name
- NCT00172783
- Where
- Taiwan
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
HIV Infections
The Effect of Bacille Calmette Guerin (BCG) Vaccination on Immune Responses in HIV-Exposed and Unexposed Infants
Background: Each year, more than half a million babies are infected with HIV by mother-to child transmission in developing countries. Many of these babies get sick and develop HIV disease (AIDS) at a very young age.
- Trial name
- NCT00331474
- Testing
- BCG delayed
- Where
- South Africa
- Volunteers
- 180 people
- Sponsor
- University of Stellenbosch
Diabetes Mellitus, Type 1, Diabetes type1
Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes
The purpose of this study is to investigate if repeat bacillus Calmette-Guérin (BCG) vaccinations can confer a beneficial immune and metabolic effect on pediatric Type 1 diabetes.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes type1, Autoimmune Diabetes
- Trial name
- NCT05180591
- Testing
- Bacillus Calmette-Guérin, Saline Injection
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Massachusetts General Hospital
Tuberculosis Infection, Tuberculosis
BCG Revaccination in Children and Adolescents
Bacille Calmette Guerin (BCG) vaccine is one of the most used vaccines of the world, to reduce the risks of natural tuberculous infection.
- Trial name
- BRiC (NCT05330884)
- Testing
- BCG vaccine, Oral Chemoprophylaxis
- Where
- India
- Volunteers
- 9,200 people, healthy volunteers welcome
- Sponsor
- Tuberculosis Research Centre, India
Bladder Cancer
Antiangiogenic Effects of BCG on Urinary Concentration of Angiogenic Factors
To determine if there is an association between basic fibroblast growth factor,vascular endothelial growth factor, and interleukin levels and a patients response to BCG treatment ( as standard treatment)in the urine of patients…
- Trial name
- NCT00216814
- Where
- Canada
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's